title: Nab-Paclitaxel or Docetaxel as Alternatives to Solvent-Based Paclitaxel in Metastatic Breast Cancer (Mbc): A Cost Utility Analysis from a Chinese Health Care Perspective.
authors.affiliation: Augmentium Pharma Consulting, Toronto, ON, Canada.
authors.forename: G
authors.initials: G
authors.lastname: Dranitsaris
authors.affiliation: Fudan University Shanghai Cancer Center, Shanghai, China.
authors.forename: B
authors.initials: B
authors.lastname: Yu
authors.affiliation: Fudan University Shanghai Cancer Center, Shanghai, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Qing
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: J
authors.initials: J
authors.lastname: King
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: A
authors.initials: A
authors.lastname: Zhang
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kaura